Agriculture & Agritech Global On demand · 24-48h

Global Poultry Liquid Vaccine Market Strategic Research Report

Global Poultry Liquid Vaccine Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Poultry Liquid Vaccine Market
$3.57B2025
6.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines

By Application: Newcastle Disease Prevention, Avian Influenza Prevention, Infectious Bronchitis Prevention, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Merck Animal Health, Zoetis, Boehringer Ingelheim, Ceva Santé Animale, HIPRA, Vaxxinova, Kemin Industries, Phibro Animal Health Corporation, Hester Biosciences, Venky's India, Elanco Animal Health, Biovac Veterinary Medicines, Choong Ang Vaccine Laboratories, Laboratorios Calier, Qingdao Yebio Bioengineering Co., Ltd., Pulike Biological Engineering, Inc., QYH Biotech Co., Ltd., Tianjin Ringpu Bio-Technology Co., Ltd., China Animal Husbandry Industry Co., Ltd., Huapai Biopharm Group Co., Ltd., Harbin Weike Biotechnology Co., Ltd., Guangzhou South China Biological Medicine Co., Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 154 pages
Market size 2025
$3.57B
Billion USD
Forecast CAGR
6.4%
2025-2032
Forecast 2032
$5.5B
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Poultry Liquid Vaccine market size is predicted to grow from US$ 3,571 million in 2025 to US$ 5,493 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

In 2025, global Poultry Liquid Vaccine production reached approximately 81.11 billion doses, with an average global market price of around USD 0.045 per dose.

The gross profit margin of major companies in the industry is between 29.48%–52.36%.

In 2025, the global production capacity of Poultry Liquid Vaccine was approximately 106.73 billion doses.

Poultry Liquid Vaccine refers to ready-to-use or diluted liquid biological preparations used to prevent infectious diseases in chickens, ducks, turkeys and other poultry. It may include live attenuated, inactivated, recombinant or vector-based vaccines delivered through injection, drinking water, spray or eye-drop routes. The product is mainly used in commercial broilers, layers, breeders and waterfowl farming to prevent diseases such as Newcastle disease, infectious bronchitis, avian influenza and infectious bursal disease. The market excludes dry powder veterinary vaccines, livestock vaccines and non-vaccine animal health products.

The industry chain includes vaccine strains, cell culture media, embryonated eggs, antigens, adjuvants, stabilizers, sterile water, vials, ampoules, cold-chain packaging and quality testing materials. Midstream production covers seed lot management, antigen culture, inactivation or attenuation, formulation, filling, inspection, batch release and cold-chain distribution. Downstream demand comes from poultry farms, hatcheries, veterinary service providers, animal health distributors and government disease prevention programs. Growth is supported by intensive poultry farming, disease control requirements, food safety standards and vaccination coverage expansion.

Large-scale intensive breeding and livestock epidemic prevention policies promote the market expansion of poultry liquid vaccines. Liquid preparation simplifies inoculation operation and improves flock immunization coverage rate. Formula stabilization and low-irritant strain screening upgrade vaccine safety and immune efficacy.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Poultry Liquid Vaccine market?

What factors are driving Poultry Liquid Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Poultry Liquid Vaccine market opportunities vary by end market size?

How does Poultry Liquid Vaccine break out by Type, by Application?

This report presents a comprehensive overview of the global Poultry Liquid Vaccine market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Recombinant Vaccines

Segment by Target Poultry

  • Chicken Vaccines
  • Duck and Goose Vaccines
  • Turkey Vaccines

Segment by Dose Volume

  • Low Dose(≤0.10 mL/bird)
  • Standard Dose(0.11–0.50 mL/bird)
  • High Dose(>0.50 mL/bird)

Segment by Application

  • Newcastle Disease Prevention
  • Avian Influenza Prevention
  • Infectious Bronchitis Prevention
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Poultry Liquid Vaccine market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Newcastle Disease Prevention, Avian Influenza Prevention, Infectious Bronchitis Prevention evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Poultry Liquid Vaccine Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$3.57B
2025
Forecast
$5.5B
2032
CAGR
6.4%
2025–2032
Regionen
5
global
Key companies
Merck Animal HealthZoetisBoehringer IngelheimCeva Santé AnimaleHIPRAVaxxinovaKemin IndustriesPhibro Animal Health Corporation
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Live Attenuated VaccinesInactivated VaccinesRecombinant Vaccines
By Application
Newcastle Disease PreventionAvian Influenza PreventionInfectious Bronchitis PreventionOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Live Attenuated Vaccines
  • 3.1.3 Inactivated Vaccines
  • 3.1.4 Recombinant Vaccines
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Newcastle Disease Prevention
  • 4.1.3 Avian Influenza Prevention
  • 4.1.4 Infectious Bronchitis Prevention
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Merck Animal Health
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Zoetis
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Boehringer Ingelheim
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Ceva Santé Animale
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 HIPRA
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Vaxxinova
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Kemin Industries
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Phibro Animal Health Corporation
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Hester Biosciences
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Venky's India
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Elanco Animal Health
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Biovac Veterinary Medicines
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Choong Ang Vaccine Laboratories
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Laboratorios Calier
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Qingdao Yebio Bioengineering Co., Ltd.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Pulike Biological Engineering, Inc.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 QYH Biotech Co., Ltd.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Tianjin Ringpu Bio-Technology Co., Ltd.
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 China Animal Husbandry Industry Co., Ltd.
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Huapai Biopharm Group Co., Ltd.
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Harbin Weike Biotechnology Co., Ltd.
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Guangzhou South China Biological Medicine Co., Ltd.
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Poultry Liquid Vaccine market?
The global Poultry Liquid Vaccine market is estimated at US$ 3.57 billion in 2025 (base year) and is projected to reach US$ 5.49 billion by 2032.
How fast is the Poultry Liquid Vaccine market expected to grow?
The market is expected to grow at a CAGR of 6.4% from 2026 to 2032, expanding from US$ 3.57 billion in 2025 to US$ 5.49 billion in 2032, roughly 1.5 times its base-year value.
What does the Poultry Liquid Vaccine market cover?
In 2025, global Poultry Liquid Vaccine production reached approximately 81.11 billion doses, with an average global market price of around USD 0.045 per dose.
How is the Poultry Liquid Vaccine market segmented by type?
By type, the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines and Recombinant Vaccines.
What are the key applications of Poultry Liquid Vaccine?
Key applications covered include Newcastle Disease Prevention, Avian Influenza Prevention, Infectious Bronchitis Prevention and Other.
Which companies are profiled in the Poultry Liquid Vaccine market report?
Key players profiled include Merck Animal Health, Zoetis, Boehringer Ingelheim, Ceva Santé Animale, HIPRA, Vaxxinova, Kemin Industries and Phibro Animal Health Corporation, among 22 companies covered in total.
What geographies does the Poultry Liquid Vaccine market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Poultry Liquid Vaccine?
Growth is supported by intensive poultry farming, disease control requirements, food safety standards and vaccination coverage expansion.
Who should buy the Poultry Liquid Vaccine market report?
The report is intended for manufacturers and solution providers, distributors and end users in Newcastle Disease Prevention, Avian Influenza Prevention and Infectious Bronchitis Prevention, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Poultry Liquid Vaccine market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.